Lin Min-Qiang, Lian Chen-Lu, Zhou Ping, Lei Jian, Wang Jun, Hua Li, Zhou Juan, Wu San-Gang
Department of Scientific Management, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
JMIR Med Inform. 2020 Nov 17;8(11):e21931. doi: 10.2196/21931.
The application of China's big data sector in cancer research is just the beginning. In recent decades, more and more Chinese scholars have used the Surveillance, Epidemiology, and End Results (SEER) database for clinical cancer research. A comprehensive bibliometric study is required to analyze the tendency of Chinese scholars to utilize the SEER database for clinical cancer research and provide a reference for the future of big data analytics.
Our study aimed to assess the trend of publications on clinical cancer research in mainland China from the SEER database.
We performed a PubMed search to identify papers published with data from the SEER database in mainland China until August 31, 2020.
A total of 1566 papers utilizing the SEER database that were authored by investigators in mainland China were identified. Over the past years, significant growth in studies based on the SEER database was observed (P<.001). The top 5 research topics were breast cancer (213/1566, 13.6%), followed by colorectal cancer (185/1566, 11.8%), lung cancer (179/1566, 11.4%), gastrointestinal cancer (excluding colorectal cancer; 149/1566, 9.5%), and genital system cancer (93/1566, 5.9%). Approximately 75.2% (1178/1566) of papers were published from the eastern coastal region of China, and Fudan University Shanghai Cancer Center (Shanghai, China) was the most active organization. Overall, 267 journals were analyzed in this study, of which Oncotarget was the most contributing journal (136/267, 50.9%). Of the 1566 papers studied, 585 (37.4%) were published in the second quartile, 489 (31.2%) in the third quartile, 312 (19.9%) in the first quartile, and 80 (5.1%) in the fourth quartile, with 100 (6.4%) having an unknown Journal Citation Reports ranking.
Clinical cancer research based on the SEER database in mainland China underwent constant and rapid growth during recent years. High-quality and comprehensive cancer databases based on Chinese demographic data are urgently needed.
中国大数据领域在癌症研究中的应用尚处于起步阶段。近几十年来，越来越多的中国学者使用监测、流行病学和最终结果（SEER）数据库进行临床癌症研究。需要进行一项全面的文献计量学研究，以分析中国学者利用SEER数据库进行临床癌症研究时的趋势，并为未来的大数据分析提供参考。
我们的研究旨在评估中国大陆利用SEER数据库发表的临床癌症研究的趋势。
我们在PubMed上进行检索，以识别截至2020年8月31日在中国大陆发表的使用SEER数据库数据的论文。
共识别出1566篇由中国大陆研究人员撰写的利用SEER数据库的论文。在过去几年中，观察到基于SEER数据库的研究显著增长（P<0.001）。排名前5的研究主题是乳腺癌（213/1566，13.6%），其次是结直肠癌（185/1566，11.8%）、肺癌（179/1566，11.4%）、胃肠道癌（不包括结直肠癌；149/1566，9.5%）和生殖系统癌（93/1566，5.9%）。约75.2%（1178/1566）的论文发表于中国东部沿海地区，复旦大学附属肿瘤医院（中国上海）是最活跃的机构。总体而言，本研究分析了267种期刊，其中《Oncotarget》是贡献最大的期刊（136/267，50.9%）。在研究的1566篇论文中，585篇（37.4%）发表在第二四分位数区间，489篇（31.2%）发表在第三四分位数区间，312篇（19.9%）发表在第一四分位数区间，80篇（5.1%）发表在第四四分位数区间，100篇（6.4%）的期刊引用报告排名未知。
近年来，中国大陆基于SEER数据库的临床癌症研究持续快速增长。迫切需要基于中国人口数据的高质量综合性癌症数据库。
